Genenta Science to Close U.S. Subsidiary and Shift CFO to Consulting Role

Genenta Science SpA Sponsored ADR ( (GNTA) ) has issued an announcement.

Genenta Science S.p.A. said on April 28, 2026, that its board has decided to cease U.S. operations and close its wholly owned Delaware subsidiary, Genenta Science, Inc., following a strategic review and a shift toward building an industrial aggregator in Italy and Europe. The wind-down, expected to be largely completed by July 31, 2026, should entail only minimal one-off charges and is not expected to materially affect the company’s overall financial position or liquidity.

As part of the U.S. closure, Chief Financial Officer Richard B. Slansky, the last remaining employee of Genenta Science, Inc., will move from an employment role to a 12‑month consulting arrangement effective June 1, 2026, while retaining his responsibilities as principal financial and accounting officer. Under the binding consulting agreement signed on April 24, 2026, Slansky will receive consulting fees and potential incentive-based compensation, providing continuity in financial oversight as Genenta consolidates its operations in Europe.

The most recent analyst rating on (GNTA) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Genenta Science SpA Sponsored ADR stock, see the GNTA Stock Forecast page.

More about Genenta Science SpA Sponsored ADR

Genenta Science S.p.A. is a Milan-based biotechnology company that develops gene-therapy-based cancer treatments, with operations historically spanning Europe and the United States. The group has focused on building an “industrial aggregator” for advanced therapies in Italy and Europe, and is now prioritizing these core markets as it refines its global footprint.

Average Trading Volume: 112,749

Technical Sentiment Signal: Sell

Current Market Cap: $16.59M

Find detailed analytics on GNTA stock on TipRanks’ Stock Analysis page.